Jefferies Healthcare Conference: How CDMOs are embracing the obesity drugs craze

Weight loss drugs known as GLP-1s have caused a stir among patients and investors, with many CDMOs now looking to tap into the booming market.

Related Keywords

Sylke Hassel ,Novo Nordisk Ozempic ,Thomas Meier ,Eli Lilly Mounjaro ,David Windley ,Van Buijtenen ,Jefferies Equity Research ,Jefferies London Healthcare ,Novo Nordisk ,Eli Lilly ,Bio Developments ,Markets Amp Regulations ,Covid 19 ,Pipelines ,Emerging Markets ,Obesity ,Diabetes ,Glp 1 ,